Here are the 424B prospectus supplements from Claritev Corporation (CTEV) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow CTEV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTEV filings page.
Claritev Corporation is registering 1,500,000 shares of its Class A common stock for resale by existing selling securityholders, with underwriters holding an option to purchase up to an additional 225,000 shares. All shares are being sold by current owners, so Claritev will not receive proceeds, though it will cover offering expenses other than underwriting discounts and commissions.
As of September 30, 2025, 16,509,496 shares of Class A common stock were outstanding. The H&F Investors group, which controlled approximately 32.6% of Claritev’s voting equity before this offering, will beneficially own about 23.5% after the base deal, or 22.2% if the underwriters’ option is fully exercised.
Claritev provides data-driven cost management solutions to healthcare payors. Its analytics, network, payment integrity and data science services target lower medical costs and better reimbursement accuracy, and identified approximately $18.6 billion in potential medical cost savings for the nine months ended September 30, 2025.